The Allergic Bronchopulmonary Aspergillosis drugs in development market research report provides comprehensive information on the therapeutics under development for Allergic Bronchopulmonary Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Allergic Bronchopulmonary Aspergillosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Allergic Bronchopulmonary Aspergillosis and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Allergic Bronchopulmonary Aspergillosis by six companies/universities/institutes. The top development phase for Allergic Bronchopulmonary Aspergillosis is preclinical with five drugs in that stage. The Allergic Bronchopulmonary Aspergillosis pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Allergic Bronchopulmonary Aspergillosis pipeline products market are: Pulmonomy, Pulmatrix and Novabiotics.
The key targets in the Allergic Bronchopulmonary Aspergillosis pipeline products market include Lanosterol 14 Alpha Demethylase, Ergosterol, and Cell Membrane.
The key mechanisms of action in the Allergic Bronchopulmonary Aspergillosis pipeline product include Lanosterol 14 Alpha Demethylase Inhibitor with two drugs in Phase II. The Allergic Bronchopulmonary Aspergillosis pipeline products include three routes of administration with the top ROA being Inhalational and two key molecule types in the Allergic Bronchopulmonary Aspergillosis pipeline products market including Small Molecule, and Synthetic Peptide.
Allergic Bronchopulmonary Aspergillosis overview
Allergic bronchopulmonary aspergillosis (ABPA) is infection of the lung with Aspergillus fumigatus fungus in those with bronchial asthma, cystic fibrosis, or a compromised immune system. The disease effects are caused by a hypersensitivity reaction to antigens of the Aspergillus species. Clinical manifestations include bronchospasm, pulmonary infiltrates, eosinophilia, and immunologic evidence of allergy to the antigens of Aspergillus species.
For a complete picture of Allergic Bronchopulmonary Aspergillosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
